Hepcinat LP

Uses
Hepcinat-LP (Hepcinat LP) is a combination of two potent antiviral agents - Ledipasvir and Sofosbuvir. It is indicated in the treatment of chronic hepatitis C virus (HCV) in certain patients. Hepcinat-LP prevents the spread of the HCV in the body, thereby decreasing the amount of HCV in the body.

Dosage and Administration
Take only the dosage prescribed by your doctor and follow all their instructions for taking this medicine.

Hepcinat-LP is a tablet that should be swallowed whole with a glass of water. It can be taken with or without food.

Side effects
Most people take Hepcinat-LP without any unwanted side effects. If you feel unwell taking this medicine, contact your doctor as soon as possible.

The most common side effects reported are headache and tiredness

If you note any signs of allergic reaction (rash, hives, excessive itching, unusual difficulty breathing, tightness in your chest, or swelling of the mouth, face, lips, or tongue) contact your doctor immediately.

Precautions
There are some situation in which Hepcinat-LP (Ledipasvir/Sofosbuvir) must not be taken. Do not take this medicine if:

• you are allergic ledipasvir or sofosbuvir
• you are already taking another medicine that has sofosbuvir in it
• you are currently taking a medicine that contains cobicistat, elvitegravir, emtricitabine, tenofovir, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, rosuvastatin, simeprevir, St. John's wort, tipranavir or ritonavir

In addition to the above contraindications, other conditions may be exacerbated by taking Hepcinat-LP, or could prevent Hepcinat-LP from working properly. Before beginning treatment, tell your doctor if you:

• are pregnant, planning to become pregnant, or are breast-feeding
• are currently taking any prescription or non-prescription drugs, herbal preparations, or dietary supplements
• are allergic to any medicines, foods, or other substances
• have liver or kidney problems

Some other medicines have have an unwanted interaction with Hepcinat-LP. In particular:

• Simeprevir because it may increase the risk of ledipasvir and sofosbuvir's side effects
• Carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, St. John's wort, or tipranavir because they may decrease ledipasvir and sofosbuvir's effectiveness
• Digoxin or rosuvastatin because the risk of their side effects may be increased by ledipasvir and sofosbuvir